(Q42977023)

English

Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.

scientific article published on October 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

amantadine sulfate

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

Gerlinde Teuber

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

M Pascu

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

M Lafrenz

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

J Pausch

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

F Kullmann

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

G Ramadori

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

R Arnold

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

H Weidenbach

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

E Musch

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

U Junge

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

K H Wiedmann

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

E Herrmann

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

M Zankel

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

S Zeuzem

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

publication date

1 October 2003

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Journal of Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

39

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

606-613

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Amantadine for chronic hepatitis c: a magic bullet or yet another dead duck?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900298-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(03)00298-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12971972%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42977023&oldid=1590407953"